# US 2024/0218036 A1 · Multi specific molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0218036 A1
- Document ID: US20240218036A1
- Status: Published application
- Kind: A1
- Application number: 18/435,494
- Filed: 2024-02-07
- Published: 2024-07-04
- Earliest claimed: 2017-11-14
- Assignees: Affilogic
- Applicants: Affilogic
- Inventors: Olivier KITTEN; Mathieu CINIER; Simon HUET
- Web page: https://patentgrep.com/patent/US20240218036A1

## CPC

- C07K 14/54: Interleukins [IL]
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/164: {from bacteria}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/195: from bacteria
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/244: {Interleukins [IL]}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 2039/505: {comprising antibodies}
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to proteins having multi-specific binding abilities by fusion of an OB-fold variant, in particular from the Sac7d family, to the light or heavy chain of an antibody.

## Claims

### Claim 1

A polypeptide comprising a modified antibody wherein at least one variant of a protein of the Sac7d family is fused to at least one heavy or light chain of the antibody, wherein the variant comprises between 4 and 20 or between 5 and 20 mutated residues in the binding site of the protein of the Sac7d family.

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein the mutated amino acids correspond to amino acids selected from V2, K3, K5, K7, Y8, K9, G10, E11, K13, E14, T17, K21, K22, W24, V26, G27, K28, M29, S31, T33, Y34, D36, N37, G38, K39, T40, R42, A44, S46, E47, K48, D49, A50 and P51 of the Sac7d protein set forth in SEQ ID NO: 1.

### Claim 3 (depends on 2)

The polypeptide of claim 2, wherein the variant contains 7 to 14 mutated amino acids corresponding to amino acids selected from K7, Y8, K9, K21, K22, W24, V26, M29, S31, T33, T40, R42, A44, and S46 of the Sac7d protein.

### Claim 4 (depends on 1)

The polypeptide of claim 1, wherein at least one variant of the protein of the Sac7d family is fused to two heavy or to two light chains of the antibody.

### Claim 5 (depends on 1)

The polypeptide of claim 1, wherein at least one variant of a protein of the Sac7d family is fused to one heavy chain and at least one variant of a protein of the Sac7d family is fused to one light chain of the antibody.

### Claim 6 (depends on 1)

The polypeptide of claim 1, wherein at least one heavy or one light chain of the antibody is fused with two variants of proteins of the Sac7d family.

### Claim 7 (depends on 1)

The polypeptide of claim 1, wherein at least two different variants of a protein of the Sac7d family are fused to the heavy and/or to the light chains of the antibody.

### Claim 8 (depends on 1)

The polypeptide of claim 1, wherein eight variants of a protein of the Sac7d family are fused to the heavy and light chains of the antibody.

### Claim 9 (depends on 1)

The polypeptide of claim 1, wherein the antibody is a therapeutic antibody.

### Claim 10 (depends on 1)

The polypeptide of claim 1, which binds to a protein selected from EGFR, VEGFR2, TfR, Her2, Mesothelin, EpCam, CD38, CD3, CD7, PD1, PD-L1, CTLA4, OX40, VEGF, TNFalpha, IL17, IL4, IL13, IL23, IL12, MAdCam, and a4b7.

### Claim 11 (depends on 1)

The polypeptide of claim 1, which binds to one of the following couples of targets:
EGFR/EGFRvIII,
EGFR/Her2,
VEGFR2/PD1,
EGFR/PD1,
VEGF/PD-L1,
PD1/OX40,
PD1/CTLA4,
EGFR/CD3,
TNFa/IL17, and
IL13/IL4.

### Claim 12 (depends on 1)

The polypeptide of claim 1, wherein the variant of a protein of the Sac7d family binds to IL17.

### Claim 13 (depends on 11)

The polypeptide of claim 11, wherein the variant of a protein of the Sac7d family comprises the amino acid sequence of SEQ ID NO: 35 or SEQ ID NO: 36.

### Claim 14 (depends on 11)

The polypeptide of claim 11 comprising the amino acid sequence of SEQ ID NO: 37 or SEQ ID NO: 38.

### Claim 15 (depends on 11)

The polypeptide of claim 11, wherein the antibody binds to a protein selected from TNFalpha, IL23, IL12, IL4, IL13, IL31 or its receptor and a tumor specific antigen.

### Claim 16 (depends on 1)

The polypeptide of claim 1, wherein the variant of a protein of the Sac7d family binds to a subunit of TNFalpha.

### Claim 17 (depends on 15)

The polypeptide of claim 15 comprising the amino acid sequence of SEQ ID NO: 39 or SEQ ID NO: 40.

### Claim 18 (depends on 15)

The polypeptide of claim 15 comprising the amino acid sequence of SEQ ID NO: 41.

### Claim 19 (depends on 15)

The polypeptide of claim 15, wherein the antibody binds to a protein selected from IL17, CD20, IL24, IL12, IL4, IL13, IL31 or its receptor and a tumor specific antigen.

### Claim 20

A genetic construct comprising a DNA sequence selected from:
(a) a sequence coding for the heavy chain of an antibody fused at its 3′ end with a sequence coding for a variant of a protein of the Sac7d family;
(b) a sequence coding for the heavy chain of an antibody fused at its 5′ end with a sequence coding for a variant of a protein of the Sac7d family;
(c) a sequence coding for the light chain of an antibody fused at its 3′ end with a sequence coding for a variant of a protein of the Sac7d family; and
(d) a sequence coding for the light chain of an antibody fused at its 5′ end with a sequence coding for a variant of a protein of the Sac7d family.

### Claim 21 (depends on 20)

A vector comprising the genetic construct of claim 20.

### Claim 22 (depends on 20)

A host cell comprising the genetic construct of claim 20 in its genome.

### Claim 23 (depends on 1)

A method for producing the polypeptide of claim 1 comprising:
(a) culturing a cell culture wherein the cells have been transformed by a genetic construct comprising a DNA sequence selected from:
(i) a sequence coding for the heavy chain of an antibody fused at its 3′ end with a sequence coding for a variant of a protein of the Sac7d family;
(ii) a sequence coding for the heavy chain of an antibody fused at its 5′ end with a sequence coding for a variant of a protein of the Sac7d family;
(iii) a sequence coding for the light chain of an antibody fused at its 3′ end with a sequence coding for a variant of a protein of the Sac7d family; and
(iv) a sequence coding for the light chain of an antibody fused at its 5′ end with a sequence coding for a variant of a protein of the Sac7d family; and
a genetic construct coding for the complementary chain of the antibody; and
(b) recovering the polypeptide.

### Claim 24 (depends on 19)

A method for maintaining or increasing production yield of a modified antibody comprising:
(a) culturing a cell culture, wherein the cells have been transformed by a genetic construct of claim 19 and a genetic construct coding for the complementary chain of the antibody, and
(b) recovering the modified antibody produced after expression of the genetic construct of step (a),
wherein the modified antibody recovered in step (b) comprises at least one variant of a protein of the Sac7d family comprising between 5 and 20 mutated residues in the binding site of the protein, and the yield of the recovered modified antibody is equal to or higher than the yield of the unmodified antibody produced under the same conditions.
